BioN­Tech inks can­cer deal with Chi­nese biotech; Eikon, CASI buy Cleave Ther­a­peu­tics’ as­sets

BioN­Tech has reached a re­search and op­tion agree­ment with Bio­theus for two an­ti­body can­di­dates.

Bio­theus an­nounced the deal Wednes­day. It will grant BioN­Tech ex­clu­sive world­wide op­tions for a pre­clin­i­cal bis­pe­cif­ic and a clin­i­cal-stage mon­o­clon­al an­ti­body for undis­closed can­cer tar­gets in ex­change for an up­front pay­ment. If BioN­Tech choos­es to li­cense the pre­clin­i­cal can­di­date, Bio­theus will get mile­stone pay­ments and roy­al­ties. The fi­nan­cial specifics were not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER